



## AMENDMENTS TO THE CLAIMS

**This listing of claims will replace all prior versions and listings of claims in the application:**

### LISTING OF CLAIMS:

1. (canceled).
2. (currently amended): A compound of formula (III) or (VIII):



wherein

R<sub>1</sub> is hydrogen,

R<sub>2</sub>, R<sub>3</sub>[[,]] and R<sub>4</sub> are independently hydrogen, hydroxy or OR<sub>9</sub>,

R<sub>7</sub> is hydroxy,

R<sub>5</sub>, R<sub>6</sub>[[, R<sub>7</sub>]] and R<sub>8</sub> are independently hydrogen, hydroxy, or C<sub>1-6</sub> alkylOR<sub>9</sub>, OC(O)R<sub>9</sub>, OS(O)R<sub>9</sub>, alkyl, aryl, arylalkyl, thiol, alkylthio, bromo, chloro or fluoro,

R<sub>9</sub> is C<sub>1-6</sub> alkyl, fluoroalkyl or arylalkyl,

one of R<sub>14</sub> and R<sub>15</sub> are independently is hydrogen, amino, cyano, thiol, nitro, or optionally substituted alkyl, haloalkyl, acyl, aryl, arylalkyl or alkylaryl, or the substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an optionally substituted cyclic heteroalkyl or heteroaromatic structure

the other one of R<sub>14</sub> and R<sub>15</sub> is hydrogen or is phenyl, benzyl, or pyridyl optionally substituted by C<sub>1-6</sub> alkyl, nitro, OR<sub>9</sub>, halo or cyano, and

the drawing "---" represents either a single bond or a double bond,

~~which compounds include~~ or a pharmaceutically acceptable salt[[s]] thereof,

~~with the proviso that the following compounds~~

~~2,3-Dihydro-2,3-diphenyl-4H-1-benzopyran-4-one hydrazone~~

~~2'-Hydroxy-isoflavanone-(2,4-dinitrophenyl)hydrazone~~

~~7-Methoxy-isoflavanone-phenylhydrazone~~

~~5,7-Dimethoxy-isoflavanone-(2,4-dinitrophenyl)hydrazone~~

~~Isoflavanone-(2,4-dinitrophenyl)hydrazone~~

~~6-Hydroxy-isoflavanone-(2,4-dinitrophenyl)hydrazone~~

~~7-Hydroxy-isoflavanone-(2,4-dinitrophenyl)hydrazone~~

~~Isoflavanone-semicarbazone~~

~~7-Methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~7-Hydroxy-4'-methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~5,7-Dimethoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~6-Methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~4',5,7-trimethoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~7-Methoxy-2-methyl-isoflavanone (2,4-dinitrophenyl)hydrazone~~

~~2-(Hydroxymethyl)-7-methoxy-isoflavanone (2,4-dinitrophenyl)hydrazone~~

and hydrochloride salts thereof are specifically excluded.

3. (currently amended): A compound according to claim [[1]]2, wherein

~~R<sub>1</sub> is hydrogen,~~

~~R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are independently hydrogen, hydroxyl, or methoxy,~~

~~R<sub>5</sub>[[,]] and R<sub>6</sub> are hydrogen, and R<sub>8</sub> are independently hydrogen, hydroxy, OR<sub>9</sub>, OC(O)R<sub>9</sub>,  
alkyl, aryl or arylalkyl,~~

~~R<sub>4</sub> and R<sub>7</sub> are independently hydroxy, OR<sub>9</sub> or OC(O)R<sub>9</sub>,~~

~~R<sub>9</sub> is methyl, ethyl, propyl, isopropyl or trifluoromethyl~~

~~R<sub>8</sub> is hydrogen or C<sub>1-6</sub> alkyl, and~~

~~the other one of R<sub>14</sub> and R<sub>15</sub> are independently is hydrogen or is phenyl, benzyl or pyridyl  
optionally substituted by methyl, nitro, methoxy, chloro or cyano, methyl, ethyl, propyl,  
isopropyl, trifluoromethyl or optionally substituted phenyl, naphthyl or benzyl, or the  
substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an  
optionally substituted cyclic heteroalkyl or heteroaromatic structure,~~

~~which compounds include~~ or a pharmaceutically acceptable salt[[s]] thereof.

4. (currently amended): A compound according to claim [[2]]3, wherein

~~R<sub>1</sub> is hydrogen,~~

~~R<sub>2</sub>[[,]] and R<sub>3</sub> are hydrogen, R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> are independently hydrogen, hydroxy, OR<sub>9</sub>,~~

~~OC(O)R<sub>9</sub> or methyl,~~

~~R<sub>4</sub> and R<sub>7</sub> are independently~~ is hydroxy or methoxy, OR<sub>9</sub> or OC(O)R<sub>9</sub>,

~~R<sub>9</sub> is methyl,~~

R<sub>8</sub> is hydrogen or methyl,

~~R<sub>14</sub> is hydrogen and R<sub>15</sub> is hydrogen, methyl, ethyl, trifluoromethyl, phenyl optionally substituted by methyl, nitro, methoxy, chloro or cyano, chlorophenyl, nitrophenyl, tolyl, naphthyl, benzyl, chlorobenzyl, nitrobenzyl or methylbenzyl, or the substituents R<sub>14</sub> and R<sub>15</sub> together with the nitrogen atom to which they are attached form an optionally substituted cyclic heteroalkyl or heteroaromatic structure, and~~

the drawing "---" represents a single bond,

~~which compounds include~~ or a pharmaceutically acceptable salt[[s]] thereof.

5. (currently amended): A compound according to claim [[3]]4 selected from compounds (1) - (10):

4',7-Dihydroxyisoflavanone (phenyl)hydrazone (1)

4',7-Dihydroxyisoflavanone (4-nitrophenyl)hydrazone (2)

4',7-Dihydroxyisoflavanone (4-methylphenyl)hydrazone (3)

4',7-Dihydroxyisoflavanone (benzyl)hydrazone (4)

4',7-Dihydroxyisoflavanone (4',7-dihydroxyisoflavanone)hydrazone (5)

4',7-Dihydroxyisoflavanone (2-chlorophenyl)hydrazone (6)

4',7-Dihydroxyisoflavanone (3-chlorophenyl)hydrazone (7)


4',7-Dihydroxyisoflavanone (4-chlorophenyl)hydrazone (8)

4',7-Dihydroxyisoflavanone (2-pyridyl)hydrazone (9)

4',7-Dihydroxyisoflavanone (4-cyanophenyl)hydrazone (10)

~~which compounds include~~ or a pharmaceutically acceptable salt[[s]] thereof.

6. (currently amended): A process for the preparation of a compound of formula (III) or (VIII) as defined in claim 2 comprising the step of reacting the 4-keto group of a compound of the formula (X):



wherein

$R_1, R_2, R_3, R_4, R_5, R_6, R_7$ [[,]] and  $R_8$  ~~and X~~ are as defined in claim [[1]]2,

X is O, and

the drawing "----" represents either a single bond or a double bond,

with a hydrazine aminating agent of formula  $H_2N-NR_{14}R_{15}$ ,

wherein one of  $R_{14}$  and  $R_{15}$  is hydrogen, and

the other one of R<sub>14</sub> and R<sub>15</sub> is hydrogen or is phenyl, benzyl, or pyridyl optionally substituted by C<sub>1-6</sub> alkyl, nitro, OR<sub>9</sub>, halo or cyano.

7. (canceled).

8. (canceled).

9. (canceled).

10. (canceled).

11. (canceled).

12. (currently amended): A method for the treatment, ~~prevention or amelioration~~ of cancer in a mammal which method comprises the step of bringing a compound of formula (III) or (VIII) as defined in claim 2 or a pharmaceutically acceptable salt ~~or derivative~~ thereof into contact with cancerous tissue in a mammal that is suffering from a tumour, such that neoplastic development in said cancerous tissue is retarded or arrested.

13. (canceled).

14. (canceled).

15. (currently amended): ~~An agent~~method for the treatment of inflammation,  
comprising the step of administering to a patient, prophylaxis or amelioration of a disease or  
~~disorder, which agent comprises~~ one or more compounds of formula (III) or (VIII) as defined in  
claim 2 or a pharmaceutically acceptable salt ~~or derivative thereof~~ to treat said inflammation.

16. (currently amended): A pharmaceutical composition which comprises one or more  
compounds of formula (III) or (VIII) as defined in claim 2 or a pharmaceutically acceptable salt ~~or~~  
~~derivative~~ thereof in association with one or more pharmaceutical carriers, excipients, auxiliaries  
and/or diluents.

17. (previously presented): A drink or food-stuff, which contains one or more  
compounds of formula (III) or (VIII) as defined in claim 2 or a pharmaceutically acceptable salt ~~or~~  
~~derivative thereof.~~

18. (canceled).

19. (currently amended): A compound selected from:

4',7-Dihydroxy-4-methylimino-isoflavan (11)

4',7-Dihydroxyisoflavanone oxime (12)

4-Amino-3',4'-dimethoxy-7-hydroxy-8-methylisoflavan (13)

N-[3',4'-dimethoxy-7-hydroxy-8-methyl-4-chromanyl)-acetamide (14)

~~which compounds include~~ and pharmaceutically acceptable salts thereof.

20. (new): The method according to claim 12, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and large cell lung cancer.